Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

Young Joo Jin, Jin Woo Lee, Jung il Lee, Sang Hoon Park, Choong Kee Park, Young Seok Kim, Sook Hyang Jeong, Yun Soo Kim, Ju Hyun Kim, Seong Gyu Hwang, Kyu Sung Rim, Hyung Joon Yim, Jae Youn Cheong, Sung Won Cho, June Sung Lee, Young Min Park, Jeong Won Jang, Chun Kyon Lee, Joo Hyun Sohn, Jin Mo YangSeungbong Han

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes.Results: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤50 and >50), HCV viral load (IU/mL) (≤7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

Original languageEnglish
Article number74
JournalBMC Gastroenterology
Volume13
Issue number1
DOIs
Publication statusPublished - 2013 Apr 29
Externally publishedYes

Fingerprint

Ribavirin
Hepacivirus
Interferons
Population
Genotype
Chronic Hepatitis C
Therapeutics
Viral Load
Fibrosis
Safety
Propensity Score
Liver
peginterferon alfa-2a
peginterferon alfa-2b

Keywords

  • Chronic hepatitis C
  • Pegylated interferon alfa-2a
  • Pegylated interferon alfa-2b
  • Ribavirin
  • Sustained virological response

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population. / Jin, Young Joo; Lee, Jin Woo; Lee, Jung il; Park, Sang Hoon; Park, Choong Kee; Kim, Young Seok; Jeong, Sook Hyang; Kim, Yun Soo; Kim, Ju Hyun; Hwang, Seong Gyu; Rim, Kyu Sung; Yim, Hyung Joon; Cheong, Jae Youn; Cho, Sung Won; Lee, June Sung; Park, Young Min; Jang, Jeong Won; Lee, Chun Kyon; Sohn, Joo Hyun; Yang, Jin Mo; Han, Seungbong.

In: BMC Gastroenterology, Vol. 13, No. 1, 74, 29.04.2013.

Research output: Contribution to journalArticle

Jin, YJ, Lee, JW, Lee, JI, Park, SH, Park, CK, Kim, YS, Jeong, SH, Kim, YS, Kim, JH, Hwang, SG, Rim, KS, Yim, HJ, Cheong, JY, Cho, SW, Lee, JS, Park, YM, Jang, JW, Lee, CK, Sohn, JH, Yang, JM & Han, S 2013, 'Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population', BMC Gastroenterology, vol. 13, no. 1, 74. https://doi.org/10.1186/1471-230X-13-74
Jin, Young Joo ; Lee, Jin Woo ; Lee, Jung il ; Park, Sang Hoon ; Park, Choong Kee ; Kim, Young Seok ; Jeong, Sook Hyang ; Kim, Yun Soo ; Kim, Ju Hyun ; Hwang, Seong Gyu ; Rim, Kyu Sung ; Yim, Hyung Joon ; Cheong, Jae Youn ; Cho, Sung Won ; Lee, June Sung ; Park, Young Min ; Jang, Jeong Won ; Lee, Chun Kyon ; Sohn, Joo Hyun ; Yang, Jin Mo ; Han, Seungbong. / Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population. In: BMC Gastroenterology. 2013 ; Vol. 13, No. 1.
@article{60e7ac4b65f7405a9d79e93d9122bb3f,
title = "Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-na{\"i}ve HCV patient in Korean population",
abstract = "Background: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).Methods: This retrospective, multi-center trial was conducted on 661 treatment-na{\"i}ve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes.Results: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤50 and >50), HCV viral load (IU/mL) (≤7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.",
keywords = "Chronic hepatitis C, Pegylated interferon alfa-2a, Pegylated interferon alfa-2b, Ribavirin, Sustained virological response",
author = "Jin, {Young Joo} and Lee, {Jin Woo} and Lee, {Jung il} and Park, {Sang Hoon} and Park, {Choong Kee} and Kim, {Young Seok} and Jeong, {Sook Hyang} and Kim, {Yun Soo} and Kim, {Ju Hyun} and Hwang, {Seong Gyu} and Rim, {Kyu Sung} and Yim, {Hyung Joon} and Cheong, {Jae Youn} and Cho, {Sung Won} and Lee, {June Sung} and Park, {Young Min} and Jang, {Jeong Won} and Lee, {Chun Kyon} and Sohn, {Joo Hyun} and Yang, {Jin Mo} and Seungbong Han",
year = "2013",
month = "4",
day = "29",
doi = "10.1186/1471-230X-13-74",
language = "English",
volume = "13",
journal = "BMC Gastroenterology",
issn = "1471-230X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

AU - Jin, Young Joo

AU - Lee, Jin Woo

AU - Lee, Jung il

AU - Park, Sang Hoon

AU - Park, Choong Kee

AU - Kim, Young Seok

AU - Jeong, Sook Hyang

AU - Kim, Yun Soo

AU - Kim, Ju Hyun

AU - Hwang, Seong Gyu

AU - Rim, Kyu Sung

AU - Yim, Hyung Joon

AU - Cheong, Jae Youn

AU - Cho, Sung Won

AU - Lee, June Sung

AU - Park, Young Min

AU - Jang, Jeong Won

AU - Lee, Chun Kyon

AU - Sohn, Joo Hyun

AU - Yang, Jin Mo

AU - Han, Seungbong

PY - 2013/4/29

Y1 - 2013/4/29

N2 - Background: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes.Results: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤50 and >50), HCV viral load (IU/mL) (≤7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

AB - Background: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes.Results: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤50 and >50), HCV viral load (IU/mL) (≤7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

KW - Chronic hepatitis C

KW - Pegylated interferon alfa-2a

KW - Pegylated interferon alfa-2b

KW - Ribavirin

KW - Sustained virological response

UR - http://www.scopus.com/inward/record.url?scp=84876789373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876789373&partnerID=8YFLogxK

U2 - 10.1186/1471-230X-13-74

DO - 10.1186/1471-230X-13-74

M3 - Article

C2 - 23627926

AN - SCOPUS:84876789373

VL - 13

JO - BMC Gastroenterology

JF - BMC Gastroenterology

SN - 1471-230X

IS - 1

M1 - 74

ER -